
How a lipid secreted by cancer tumours stops the immune system from mounting an immune response against it was discovered by T cell researchers.
When lysophosphatidic acid (LPA) binds to killer T cells, it acts almost like an "invisibility cloak," preventing T cells from recognizing and attacking nascent tumours.
Advertisement
Senior author Raul Torres, PhD, professor of immunology at National Jewish Health, said that in recent years, several therapeutic medicines have been developed that spur a person's own immune system to fight cancer.
Scientists have known that LPA is secreted by many types of cancer cells, appears to promote the growth and spread of tumor cells, and that immune cells known as CD-8 "killer" T cells have several receptors for LPA. Killer T cells can destroy cancer cells when activated against them.
Researchers led by Dr. Torres showed that LPA keeps T cells inactivated even after they have "seen" a target, or antigen, on a cancer cell that would normally trigger an immune response.
They identified the LPA5 receptor as the specific receptor responsible for inhibiting the immune response. In cell cultures and in mice LPA prevented signaling within cells, the appearance of molecules associated with T-cell activation, and proliferation of the T cells.
When they transferred T cells lacking the LPA5 receptor into mice with cancer, tumor growth essentially halted.
The study has been published in journal Cancer Immunology Research.
Source: ANI
Advertisement
Researchers led by Dr. Torres showed that LPA keeps T cells inactivated even after they have "seen" a target, or antigen, on a cancer cell that would normally trigger an immune response.
They identified the LPA5 receptor as the specific receptor responsible for inhibiting the immune response. In cell cultures and in mice LPA prevented signaling within cells, the appearance of molecules associated with T-cell activation, and proliferation of the T cells.
When they transferred T cells lacking the LPA5 receptor into mice with cancer, tumor growth essentially halted.
The study has been published in journal Cancer Immunology Research.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News

The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.

Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.

The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.

Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.

Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.